Analysts Set Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) PT at $28.67

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLXGet Free Report) have been assigned an average rating of “Hold” from the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $28.67.

AMLX has been the topic of several research analyst reports. Leerink Partnrs cut Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, March 11th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Amylyx Pharmaceuticals in a report on Friday, May 10th. Evercore ISI restated an “in-line” rating on shares of Amylyx Pharmaceuticals in a report on Friday, March 8th. SVB Leerink cut Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, March 11th. Finally, Robert W. Baird cut Amylyx Pharmaceuticals from an “outperform” rating to a “neutral” rating in a report on Monday, March 11th.

Get Our Latest Report on AMLX

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in AMLX. Stonepine Capital Management LLC lifted its holdings in Amylyx Pharmaceuticals by 124.4% in the third quarter. Stonepine Capital Management LLC now owns 2,515,868 shares of the company’s stock valued at $46,066,000 after acquiring an additional 1,394,840 shares during the last quarter. Farallon Capital Management LLC acquired a new position in Amylyx Pharmaceuticals in the first quarter valued at approximately $3,267,000. Adage Capital Partners GP L.L.C. lifted its holdings in Amylyx Pharmaceuticals by 121.3% in the third quarter. Adage Capital Partners GP L.L.C. now owns 1,700,200 shares of the company’s stock valued at $31,131,000 after acquiring an additional 932,000 shares during the last quarter. Avidity Partners Management LP lifted its holdings in Amylyx Pharmaceuticals by 94.9% in the third quarter. Avidity Partners Management LP now owns 1,756,940 shares of the company’s stock valued at $32,170,000 after acquiring an additional 855,540 shares during the last quarter. Finally, Franklin Resources Inc. lifted its holdings in Amylyx Pharmaceuticals by 114.4% in the fourth quarter. Franklin Resources Inc. now owns 1,325,001 shares of the company’s stock valued at $19,504,000 after acquiring an additional 707,134 shares during the last quarter. 95.84% of the stock is currently owned by institutional investors and hedge funds.

Amylyx Pharmaceuticals Stock Performance

AMLX stock opened at $1.76 on Tuesday. Amylyx Pharmaceuticals has a 12-month low of $1.65 and a 12-month high of $26.44. The stock has a market cap of $119.70 million, a price-to-earnings ratio of -1.64 and a beta of -0.68. The business’s 50-day moving average is $2.01 and its 200 day moving average is $9.48.

Amylyx Pharmaceuticals (NASDAQ:AMLXGet Free Report) last posted its quarterly earnings data on Friday, May 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.70). Amylyx Pharmaceuticals had a positive return on equity of 4.14% and a negative net margin of 17.86%. The firm had revenue of $88.64 million during the quarter, compared to analyst estimates of $113.26 million. During the same quarter in the previous year, the firm posted $0.02 earnings per share. As a group, equities analysts forecast that Amylyx Pharmaceuticals will post -1.36 EPS for the current fiscal year.

Amylyx Pharmaceuticals Company Profile

(Get Free Report

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.

See Also

Analyst Recommendations for Amylyx Pharmaceuticals (NASDAQ:AMLX)

Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.